Vaccination for Group B Streptococcus during pregnancy: Attitudes and concerns of women and health care providers

San Patten, Ardene Robinson Vollman, Shannon D. Manning, Melissa Mucenski, Jeanne Vidakovich, H. Dele Davies

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Group B Streptococcus (GBS) is the leading infectious cause of neonatal morbidity and mortality. Although intrapartum antibiotic prophylaxis (IAP) strategies are effective in preventing GBS transmission from mothers to newborns, there are growing concerns about adverse effects, and the development of antibiotic resistance. GBS vaccines targeting the most virulent neonatal disease serotypes are currently under development and may be used during pregnancy. The objective of this study was to explore the key issues and concerns that would be associated with GBS vaccination during pregnancy from the perspectives of pregnant women and health care providers. Twenty-two women and 25 health care professionals in Alberta, Canada participated in 10 focus groups, each group ranging from 2 to 20 participants. Valuable information emerged from the focus groups about the factors that would affect acceptance of a maternal GBS vaccine. This information will be essential for health systems to consider in the introduction, promotion and delivery of such a vaccine. The data may help optimize education about GBS and a putative vaccine to pregnant women.

Original languageEnglish (US)
Pages (from-to)347-358
Number of pages12
JournalSocial Science and Medicine
Volume63
Issue number2
DOIs
StatePublished - Jul 1 2006

Fingerprint

Streptococcus agalactiae
vaccination
vaccine
Women's Health
pregnancy
Health Personnel
health care
Vaccination
Pregnancy
Vaccines
Group
Focus Groups
Infant, Newborn, Diseases
antibiotic resistance
Pregnant Women
morbidity
Mothers
antibiotics
targeting
Alberta

Keywords

  • Canada
  • Group B streptococcus
  • Immunization
  • Neonatal infection
  • Pregnancy
  • Streptococcus agalactiae
  • Vaccine

ASJC Scopus subject areas

  • Health(social science)
  • History and Philosophy of Science

Cite this

Vaccination for Group B Streptococcus during pregnancy : Attitudes and concerns of women and health care providers. / Patten, San; Vollman, Ardene Robinson; Manning, Shannon D.; Mucenski, Melissa; Vidakovich, Jeanne; Davies, H. Dele.

In: Social Science and Medicine, Vol. 63, No. 2, 01.07.2006, p. 347-358.

Research output: Contribution to journalArticle

Patten, San ; Vollman, Ardene Robinson ; Manning, Shannon D. ; Mucenski, Melissa ; Vidakovich, Jeanne ; Davies, H. Dele. / Vaccination for Group B Streptococcus during pregnancy : Attitudes and concerns of women and health care providers. In: Social Science and Medicine. 2006 ; Vol. 63, No. 2. pp. 347-358.
@article{989900837d904f0a9b280eb391ac691e,
title = "Vaccination for Group B Streptococcus during pregnancy: Attitudes and concerns of women and health care providers",
abstract = "Group B Streptococcus (GBS) is the leading infectious cause of neonatal morbidity and mortality. Although intrapartum antibiotic prophylaxis (IAP) strategies are effective in preventing GBS transmission from mothers to newborns, there are growing concerns about adverse effects, and the development of antibiotic resistance. GBS vaccines targeting the most virulent neonatal disease serotypes are currently under development and may be used during pregnancy. The objective of this study was to explore the key issues and concerns that would be associated with GBS vaccination during pregnancy from the perspectives of pregnant women and health care providers. Twenty-two women and 25 health care professionals in Alberta, Canada participated in 10 focus groups, each group ranging from 2 to 20 participants. Valuable information emerged from the focus groups about the factors that would affect acceptance of a maternal GBS vaccine. This information will be essential for health systems to consider in the introduction, promotion and delivery of such a vaccine. The data may help optimize education about GBS and a putative vaccine to pregnant women.",
keywords = "Canada, Group B streptococcus, Immunization, Neonatal infection, Pregnancy, Streptococcus agalactiae, Vaccine",
author = "San Patten and Vollman, {Ardene Robinson} and Manning, {Shannon D.} and Melissa Mucenski and Jeanne Vidakovich and Davies, {H. Dele}",
year = "2006",
month = "7",
day = "1",
doi = "10.1016/j.socscimed.2005.11.044",
language = "English (US)",
volume = "63",
pages = "347--358",
journal = "Social Science and Medicine",
issn = "0277-9536",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Vaccination for Group B Streptococcus during pregnancy

T2 - Attitudes and concerns of women and health care providers

AU - Patten, San

AU - Vollman, Ardene Robinson

AU - Manning, Shannon D.

AU - Mucenski, Melissa

AU - Vidakovich, Jeanne

AU - Davies, H. Dele

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Group B Streptococcus (GBS) is the leading infectious cause of neonatal morbidity and mortality. Although intrapartum antibiotic prophylaxis (IAP) strategies are effective in preventing GBS transmission from mothers to newborns, there are growing concerns about adverse effects, and the development of antibiotic resistance. GBS vaccines targeting the most virulent neonatal disease serotypes are currently under development and may be used during pregnancy. The objective of this study was to explore the key issues and concerns that would be associated with GBS vaccination during pregnancy from the perspectives of pregnant women and health care providers. Twenty-two women and 25 health care professionals in Alberta, Canada participated in 10 focus groups, each group ranging from 2 to 20 participants. Valuable information emerged from the focus groups about the factors that would affect acceptance of a maternal GBS vaccine. This information will be essential for health systems to consider in the introduction, promotion and delivery of such a vaccine. The data may help optimize education about GBS and a putative vaccine to pregnant women.

AB - Group B Streptococcus (GBS) is the leading infectious cause of neonatal morbidity and mortality. Although intrapartum antibiotic prophylaxis (IAP) strategies are effective in preventing GBS transmission from mothers to newborns, there are growing concerns about adverse effects, and the development of antibiotic resistance. GBS vaccines targeting the most virulent neonatal disease serotypes are currently under development and may be used during pregnancy. The objective of this study was to explore the key issues and concerns that would be associated with GBS vaccination during pregnancy from the perspectives of pregnant women and health care providers. Twenty-two women and 25 health care professionals in Alberta, Canada participated in 10 focus groups, each group ranging from 2 to 20 participants. Valuable information emerged from the focus groups about the factors that would affect acceptance of a maternal GBS vaccine. This information will be essential for health systems to consider in the introduction, promotion and delivery of such a vaccine. The data may help optimize education about GBS and a putative vaccine to pregnant women.

KW - Canada

KW - Group B streptococcus

KW - Immunization

KW - Neonatal infection

KW - Pregnancy

KW - Streptococcus agalactiae

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33646829756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646829756&partnerID=8YFLogxK

U2 - 10.1016/j.socscimed.2005.11.044

DO - 10.1016/j.socscimed.2005.11.044

M3 - Article

C2 - 16545514

AN - SCOPUS:33646829756

VL - 63

SP - 347

EP - 358

JO - Social Science and Medicine

JF - Social Science and Medicine

SN - 0277-9536

IS - 2

ER -